Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
16923411
Public Release Type:
Journal
Publication Year: 2006
Affiliation: Rhode Island Hospital, Providence, RI 02903, USA.
DOI:
https://doi.org/10.1016/j.ahj.2006.03.004
Authors:
FAVORIT Investigators,
Bostom AG,
Carpenter MA,
Kusek JW,
Hunsicker LG,
Pfeffer MA,
Levey AS,
Jacques PF,
McKenney J
Studies:
Folic Acid for Vascular Outcome Reduction in Transplantation Trial
Patients with chronic kidney disease, including kidney transplant recipients, are at high risk for cardiovascular disease (CVD). In addition to the constellation of traditional CVD risk factors in chronic kidney disease, elevated total homocysteine (tHcy) is notably more prevalent among the general population. The Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial is designed to evaluate whether lowering tHcy using vitamin supplementation reduces CVD events in renal transplant recipients.
